NDAINJECTIONINJECTABLE
Approved
May 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
OPTIRAY 320 (ioversol) by Guerbet is x-ray contrast activity [moa]. Approved for renal impairment, coronary artery disease, diabetes mellitus and 1 more indications. First approved in 1998.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPTIRAY 320 (ioversol) is a radiographic contrast agent administered by injection to enhance visualization during X-ray imaging procedures. It is indicated for patients with renal impairment, coronary artery disease, diabetes mellitus, and hypothyroidism undergoing diagnostic imaging. The drug works through X-ray contrast activity to improve radiological image quality.
LOE Approaching
As LOE approaches, commercial teams face portfolio transition pressure; expect consolidation of marketing resources and focus on retention-based strategies rather than growth initiatives.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications (4)
Worked on OPTIRAY 320 at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.